The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
Hizal, M.; Bilgin, B.; Paksoy, N.; Açıkgöz, Ö.; Sezer, A.; Gürbüz, M.; Ak, N.; Yücel, Ş.; Ayhan, M.; Erol, C.; Demirkıran, A.; Mandel, N.M.; Shbair, A.; Gökmen, İ.; Başoğlu, T.; Paydaş, S.; Demiray, A.G.; İriağaç, Y.; Şakalar, T.; Zeynelgil, E.; Tatlı, A.M.; Bahçeci, A.; Güven, D.C.; Caner, B.; Can, A.; Gülmez, A.; Karakaş, Y.; Yalçın, B.; Demirkazık, A.; Bilici, A.; Aydıner, A.; Yumuk, P.F.; Şendur, M.A.N.
Tarih:
2022
Özet:
Introduction: Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods: This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results: Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3–4 adverse events were seen in 11.7% of the patients. Conclusion: Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Tüm öğe kaydını göster